



(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 31/444 (2006.01)
A61K 31/415 (2006.01) A61P 13/08 (2006.01)
A61K 31/4166 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/040691

(22) International Filing Date:

02 August 2024 (02.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/517,672	04 August 2023 (04.08.2023)	US
63/603,336	28 November 2023 (28.11.2023)	US
63/617,895	05 January 2024 (05.01.2024)	US
63/670,485	12 July 2024 (12.07.2024)	US

(71) Applicant: **ORIC PHARMACEUTICALS, INC.**

[US/US]; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventors: **FRIEDMAN, Lori S.**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US).

JUNTILA, Melissa R.; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US). **DAEMEN, Anneleen**; 240 E. Grand Avenue, 2nd Floor, South

San Francisco, California 94080 (US). **MULTANI, Pratik Sharad**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US). **MANEVAL, Edna Chow**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US). **PANUWAT, Matthew Paul**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US).


(74) Agent: **BONNEFOUS, Celine** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: TREATMENT OF PROSTATE CANCER

FIG. 1



(57) Abstract: The present disclosure relates to methods of treating prostate cancer in a subject, comprising administering to the subject (a) an androgen receptor inhibitor, and (b) an embryonic ectoderm development (EED) inhibitor, including those methods wherein the prostate cancer has been determined to be resistant to one or more androgen receptor signaling inhibitors (ARSI), including abiraterone.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*